Symyx Partners with Simulations Plus to Improve Predictive Modeling of Metabolites and Metabolic Pathways
SUNNYVALE, Calif., March 23, 2010 – Symyx Technologies, Inc. (NASDAQ: SMMX) today announced a partnership with Simulations Plus, Inc. (NASDAQ: SLP) to improve the predictive modeling of metabolites. Under the terms of the agreement, Simulations Plus will use information from the highly regarded Symyx Metabolite database to develop a new system for in silico predictive modeling of metabolic properties, enabling R&D organizations to improve compound design, drive down experiment costs, and reduce late product failures.
“We are very pleased to be working with Simulations Plus on a tool that will improve the reliability of metabolic biotransformation modeling for ADMET researchers,” said Randy Haldeman, senior vice president of Symyx’s content business unit. “The Symyx Metabolite database is a quality collection of metabolic information upon which to optimize this powerful new mathematical model.”
The improved model will be incorporated into a new Symyx Metabolite module which is currently expected to be offered as part of the Simulations Plus ADMET Predictor™ software suite later this year. The Simulations Plus software supports advanced predictive modeling of ADMET properties associated with the absorption, distribution, metabolism, elimination, and toxicity of chemical substances in the human body.
“Simulations Plus looks forward to developing new descriptors and methods for modeling metabolism in partnership with Symyx,” said Walt Woltosz, chairman & CEO, Simulations Plus. “One of our explicit aims is the development of a predictive mathematical model that will be capable of identifying specific sites of metabolism.”
As the largest collection of drug metabolism data in the world, Symyx Metabolite provides comprehensive coverage of xenobiotic transformations and metabolic schemes from respected published sources, as well as non-proprietary metabolism studies from new drug applications published by the US Food and Drug Administration. This information helps researchers better understand degradation pathways of known compounds in humans and lab animals.
For more information about the Symyx Metabolite database and other Symyx content and workflow solutions, visit www.symyx.com or contact inforequest@symyx.com.
About Symyx
Symyx Technologies, Inc. (NASDAQ: SMMX) helps R&D-based companies in life sciences, chemicals, energy, and consumer and industrial products achieve breakthroughs in innovation, productivity, and return on investment. Symyx software and scientific databases power laboratories with the information that generates insight, enhances collaboration, and drives productivity. Products include a market-leading electronic laboratory notebook, decision support software, and chemical informatics and sourcing databases. Information about Symyx, including reports and other information filed by Symyx with the Securities and Exchange Commission, is available at www.symyx.com.
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by pharmaceutical, biotechnology, and drug delivery companies worldwide. The Company’s Words+ subsidiary, which provides assistive technology for persons with disabilities, and two retail products, Abbreviate! and FutureLab™, comprise the remainder of the business. Simulations Plus is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit the company’s Web site at www.simulations-plus.com.
